Specht | Division of Hematology & Oncology

Dr. Jennifer M. Specht

Claim this profile

Seattle Cancer Care Alliance / University of Washington

Expert in Breast Cancer
Studies Breast cancer
11 reported clinical trials
20 drugs studied

Area of expertise

1Breast Cancer
Global Leader
Jennifer M. Specht has run 11 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
Stage III
2Breast Cancer
Jennifer M. Specht has run 5 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
Stage IV
HER2 negative

Affiliated Hospitals

Image of trial facility.
Seattle Cancer Care Alliance / University Of Washington
Image of trial facility.
Fred Hutchinson Cancer Center

Clinical Trials Jennifer M. Specht is currently running

Image of trial facility.

CAR T-Cell Preparation

for Cancer

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Recruiting1 award N/A3 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

More about Jennifer M. Specht

Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Jennifer M. Specht has experience with
  • Fludeoxyglucose F-18
  • Pembrolizumab
  • Ladiratuzumab Vedotin
  • Trastuzumab
  • Niraparib
  • Computed Tomography

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jennifer M. Specht specialize in?
Is Jennifer M. Specht currently recruiting for clinical trials?
Are there any treatments that Jennifer M. Specht has studied deeply?
What is the best way to schedule an appointment with Jennifer M. Specht?
What is the office address of Jennifer M. Specht?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security